Stockscreener 앱 받기
1.63
3.82%
0.06
시간 외 거래:
1.63
전일 마감가:
$1.57
열려 있는:
$1.57
하루 거래량:
779.48K
Relative Volume:
0.73
시가총액:
$176.50M
수익:
$27.08M
순이익/손실:
$-37.00M
주가수익비율:
-3.1346
EPS:
-0.52
순현금흐름:
$-18.46M
1주 성능:
+6.54%
1개월 성능:
+12.41%
6개월 성능:
-34.54%
1년 성능:
+39.32%
1일 변동 폭
$1.57
$1.6498
1주일 범위
$1.50
$1.6498
52주 변동 폭
$1.05
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
명칭
Aclaris Therapeutics Inc
전화
484-324-7933
주소
701 LEE ROAD, WAYNE, PA
ACRS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
1.63 | 167.84M | 27.08M | -37.00M | -18.46M | -0.52 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Piper Sandler | Overweight |
| 2025-05-28 | 개시 | Wedbush | Outperform |
| 2025-03-18 | 재개 | Cantor Fitzgerald | Overweight |
| 2024-12-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2024-11-20 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2024-11-19 | 업그레이드 | Jefferies | Hold → Buy |
| 2024-11-19 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | 개시 | Evercore ISI | Outperform |
| 2022-12-14 | 개시 | Stifel | Buy |
| 2022-12-01 | 개시 | Goldman | Buy |
| 2022-10-06 | 개시 | BTIG Research | Buy |
| 2021-07-23 | 재개 | Jefferies | Buy |
| 2021-06-15 | 개시 | Piper Sandler | Overweight |
| 2021-04-21 | 개시 | H.C. Wainwright | Buy |
| 2019-10-22 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | 개시 | SVB Leerink | Outperform |
| 2018-03-28 | 재개 | Leerink Partners | Outperform |
| 2018-02-09 | 개시 | Guggenheim | Buy |
| 2017-06-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-29 | 개시 | Leerink Partners | Outperform |
| 2016-09-30 | 개시 | JMP Securities | Mkt Outperform |
| 2016-06-10 | 개시 | Guggenheim | Buy |
| 2015-11-02 | 개시 | Citigroup | Buy |
| 2015-11-02 | 개시 | Jefferies | Buy |
모두보기
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - simplywall.st
Earnings Beat: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts - uk.finance.yahoo.com
Aclaris Therapeutics Reports Q2 2025 Earnings, Highlights Clinical Advancements and Financial Metrics. - AInvest
Aclaris Therapeutics (ACRS) Reports Q2 Loss, Beats Revenue Estimates - MSN
Aclaris Therapeutics Reports Q2 Loss, Highlights Progress in Immuno-Dermatology Pipeline - MSN
Aclaris Reports Positive Phase 2a Results for ATI-2138 in Atopic Dermatitis Trial - MSN
Aclaris Therapeutics Reports Q2 2025 Results and Updates - TipRanks
Aclaris: Q2 Earnings Snapshot - Chron
Aclaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Aclaris Therapeutics reports Q2 EPS (13c), consensus (13c) - TipRanks
Aclaris Therapeutics Inc earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Aclaris Therapeutics shares rise 3.23% premarket after reporting Q2 earnings that met Wall Street expectations. - AInvest
Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Leerink Partners Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $7 - 富途牛牛
Relief Rally in Aclaris Therapeutics Inc. Stock — Can It HoldFree Membership Group - beatles.ru
What drives Aclaris Therapeutics Inc. stock priceMaximize your returns with smart trade entries - Jammu Links News
Aclaris Therapeutics Taps Veteran Biotech Leader Roland Kolbeck as New Chief Scientific Officer - MSN
How many analysts rate Aclaris Therapeutics Inc. as a “Buy”Invest confidently with professional market insights - Jammu Links News
What are Aclaris Therapeutics Inc. company’s key revenue driversTriple-digit profit margins - Jammu Links News
Is Aclaris Therapeutics Inc. a growth stock or a value stockDiscover undervalued opportunities early - Jammu Links News
What is the dividend policy of Aclaris Therapeutics Inc. stockCapitalize on emerging market trends - Jammu Links News
Is Aclaris Therapeutics Inc. a good long term investmentCapitalize on market trends before they peak - Jammu Links News
What analysts say about Aclaris Therapeutics Inc. stockMarket-leading growth rates - Jammu Links News
What is the risk reward ratio of investing in Aclaris Therapeutics Inc. stockUnmatched profit potential - Jammu Links News
What are the latest earnings results for Aclaris Therapeutics Inc.Discover market opportunities with expert help - Jammu Links News
What catalysts could drive Aclaris Therapeutics Inc. stock higher in 2025Unlock powerful market analysis and alerts - Jammu Links News
Aclaris Therapeutics Inc expected to post a loss of 13 cents a shareEarnings Preview - TradingView
How volatile is Aclaris Therapeutics Inc. stock compared to the marketBreakout Stocks Watchlist That Work - jammulinksnews.com
Is it the right time to buy Aclaris Therapeutics Inc. stockDaily Trading Report For Consistent Profits - Jammu Links News
Is Aclaris Therapeutics Inc. stock bottoming outTechnical Screener for High Growth Stocks - Newser
Is a relief rally coming for Aclaris Therapeutics Inc. holdersTechnical Stock Breakout Predictions Signal Entry Points - metal.it
Will Aclaris Therapeutics Inc. outperform the marketRisk Shielded Trade Watch with Analysis - Newser
Analysts Boost Healthcare Stocks: Aclaris Therapeutics and Nuvation Bio - AInvest
Aclaris Therapeutics Inc. Breaks Below Key Support LevelQuick Gain Stock Watch With Indicators Reviewed - metal.it
Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Market reaction to Aclaris Therapeutics Inc.’s recent newsEntry Alert Based on Volume Spikes Detected - metal.it
Stock Market Today: US Future Edge Higher Ahead Of FOMC Decision—Meta, Microsoft Earnings In Focus - Benzinga
Momentum divergence signals in Aclaris Therapeutics Inc. chartAI Model Forecasting Reversal and Breakout Zones - Newser
Aclaris Therapeutics Stock Spikes In After‑Hours Session Following Major Announcement - Benzinga
Aclaris Therapeutics Announces Positive Top-Line Results - GlobeNewswire
Aclaris Therapeutics stock soars after positive Phase 2a trial results By Investing.com - Investing.com South Africa
Aclaris Therapeutics stock soars after positive Phase 2a trial results - Investing.com Australia
Aclaris Therapeutics Announces Positive Phase 2a Trial Results - TipRanks
Aclaris reports positive results from ATI-2138 atopic dermatitis trial By Investing.com - Investing.com Nigeria
Aclaris Therapeutics Inc (ACRS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):